Fusion and Niowave ink $5M collaboration

2020 07 20 23 40 0607 Handshake Meeting 400

McMaster University spin-off company Fusion Pharmaceuticals and superconducting accelerator technology firm Niowave have inked a $5 million supply agreement for the development, production, and supply of actinium-225.

The cash will support Niowave's efforts to increase its production of actinium-225. As part of the deal, Fusion will have guaranteed access to a predetermined percentage of the radiopharmaceutical as well as preferred access to any excess supply.

Fusion is developing actinium-based targeted alpha therapy. Actinium-225 decay kills tumor cell DNA, it said. The company already has existing agreements with Canadian particle accelerator center TRIUMF and the U.S. Department of Energy.

Page 1 of 461
Next Page